Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another Indian CRO Under EMA Lens Over Dirty Data Concerns

Executive Summary

Micro Therapeutic Research Labs is now under the scanner over alleged data integrity concerns. European Medicines Agency (EMA) is evaluating medicines based on studies done by the Indian firm.

You may also be interested in...



India Global Trial Hub Dreams Still Distant As Concerns Linger

Indian clinical trial approvals appear to be on the downswing despite government moves to boost the troubled sector, as regulatory uncertainty and negative publicity continue to undermine confidence in the industry.

The ECG curse: India's Quest under lens in ''retrospective'' finding

Just when things appeared to be on an uptick, India's beleaguered clinical research industry may be headed for another trough with yet another leading CRO now under fire over data integrity concerns.

Respiratory Plus: Cipla Shapes Future In New Age Platforms, Devices, Diagnostics

The next chapter of Cipla’s innovation journey goes beyond its core respiratory thrust to include new platforms spanning areas such as peptides, where it has seen its first major approval in the US and has multiple programs lined up. Devices and diagnostics are among the other avenues being explored as the Indian company seeks to bring more patients into the “funnel”.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel